BAFO Submission definition

BAFO Submission means a selected Qualifying Bidder's response to the BAFO Document;
Sample 1Sample 2Sample 3
BAFO Submission means a selected Qualifying Bidder's response to the BAFO Documentation.
Sample 1Sample 2
BAFO Submission means the documents entitled Merseyrail Electrics BAFO Submission submitted to DLA Solicitors (as agents for the Awarding Authority and the SRA) by the Bidding Consortium, on behalf of the Concessionaire and dated 24 January 2003.
Sample 1

Examples of BAFO Submission in a sentence

  • Bidder Group Two or more persons acting together as a consortium for the purposes of any PQ, EPQ, QTT, ITT or BAFO Submission to Ofgem in accordance with the Tender Regulations.

  • If a Qualifying Bidder decides not to make a BAFO Submission for a Qualifying Project, it must notify Ofgem in writing via the Portal as soon as reasonably possible after having made such decision.

  • Best and Final Offers (BAFOs) shall be organized and provided per the instructions of Section 3.3, Final Bids, except that all changes shall be marked with tracked changes, and shall include an Executive Summary of changes, with a corresponding statement, as described in Section 4.3.3, BAFO Submission.

  • The Referee will render his or her decision in writing, with detailed reasons, and shall provide a copy of the decision to each Party within 5 Business Days of the BAFO Submission Date or such later date as the Parties may agree in writing (the “Referee Review Period”).

  • Ofgem may decline to consider a BAFO Submission where Ofgem determines that it does not comply with the requirements specified in the BAFO Document.

  • This ensures that the OFTO is not affected by underlying movements in market rates, including bond spreads, since its ITT Submission or BAFO Submission if applicable.

  • Ofgem may decline to consider a BAFO Submission made to it where Ofgem determines that the Submission does not comply with the requirements specified in the BAFO Documentation.

  • Ofgem may invite one or more Qualifying Bidder(s) to make a BAFO Submission.

  • Commence Pre-Qualification Pre-Qualification Announced Bidding Commenced Bid Submitted Preferred Bidders Selected BAFO Submission Award PPP and PPA Agreements Signed and in Force […] […]Disbursement Arrangements Out-of-pocket expenses will be paid by the executing agency at cost within an agreed ceiling.

  • The documentation will include: the rules particular to the BAFO Stage; the timeline for the stage, including an overview of the key activities and steps; a description of the information required by Ofgem for the making of a BAFO Submission, and the date, time and manner in which this Submission should be made to Ofgem; and the criteria against which Ofgem will evaluate each BAFO Submission.


More Definitions of BAFO Submission

BAFO Submission means the Tender.
Sample 1

Related to BAFO Submission

  • Regulatory Submissions means all applications, filings, dossiers and the like submitted to a Governmental Authority for the purpose of obtaining Regulatory Approval.

  • Regulatory Filing means any filing with any Governmental Authority with respect to the research, development, manufacture, distribution, pricing, reimbursement, marketing or sale of a Product.

  • Approval Application means a BLA, NDA or similar application or submission for a Product filed with a Regulatory Authority in a country or group of countries to obtain marketing approval for a biological or pharmaceutical product in that country or group of countries.

  • Planning Submission or “CAPS” or “Community Accountability Planning Submission” means the HSP Board approved planning document submitted by the HSP to the LHIN. The form, content and scheduling of the Planning Submission will be identified by the LHIN;

  • Regulatory Approval Application means any application submitted to an appropriate Regulatory Authority seeking any Regulatory Approval.

  • Drug Approval Application means an application for Regulatory Approval required before commercial sale or use of a Product as a drug in a regulatory jurisdiction.

  • Selected submission means and refers to the submission sent to the City of Waco by the Selected Firm.

  • Subject of a Clinical Trial means the health care service, item, or drug that is being evaluated in the Approved Clinical Trial and that is not a Routine Patient Cost.

  • Marketing Approval Application or “MAA” means a New Drug Application (or its equivalent), as defined in the U.S. Food, Drug and Cosmetic Act and the regulations promulgated thereunder, or any corresponding or similar application, registration or certification in any country.

  • IND means (a) an Investigational New Drug Application as defined in the FD&C Act and applicable regulations promulgated thereunder by the FDA, or (b) the equivalent application to the equivalent agency in any other regulatory jurisdiction, the filing of which is necessary to initiate or conduct clinical testing of a pharmaceutical product in humans in such jurisdiction.

  • Regulatory Materials means, with respect to a Licensed Product for any particular indication in any particular jurisdiction, regulatory applications and submissions (and any supplements or amendments thereto), and any notifications, communications, correspondence, registrations, drug master files, Regulatory Approvals and/or other filings made to, received from or otherwise conducted with a Regulatory Authority, including BLAs and INDs, as applicable, that relate to such Licensed Product in such jurisdiction. Regulatory Materials also include presentations, responses, and applications for Regulatory Approvals.

  • Electronic Submission means a successful submittal of Offeror’s proposal.

  • Regulatory Filings means any submission to a Regulatory Authority of any appropriate regulatory application together with any related correspondence and documentation, and will include any submission to a regulatory advisory board, marketing authorization application, and any supplement or amendment thereto.

  • BLA means a Biologics License Application under the United States’ Public Health Services Act and Federal Food, Drug and Cosmetics Act, each as amended, and the regulations promulgated thereunder, or a comparable filing seeking Regulatory Approval in any country.

  • Marketing Authorization Application or “MAA” means an application for Regulatory Approval in a country, territory or possession.

  • Application Review Start Date means the later date of either the date on which the District issues its written notice that the Applicant has submitted a completed Application or the date on which the Comptroller issues its written notice that the Applicant has submitted a completed Application and as further identified in Section 2.3.A of this Agreement.

  • Third-Party Filer means an entity that submits a Product filing to the Commission on behalf of an Insurer.

  • FDA means the United States Food and Drug Administration and any successor agency thereto.

  • NDA means a New Drug Application, as defined in the regulations promulgated by the United States Food and Drug Administration, or any foreign equivalent thereof.

  • Submission Deadline means 1:00 P.M., New York City time, on any Auction Date or such other time on any Auction Date as may be specified by the Auction Agent from time to time as the time by which each Broker-Dealer must submit to the Auction Agent in writing all Orders obtained by it for the Auction to be conducted on such Auction Date.

  • Bid Submission Date means the last date by which the City will accept Bids for an Invitation For Bid.

  • Development Application means the development application identified in Item 5 of Schedule 1 and includes all plans, reports models, photomontages, material boards (as amended supplemented) submitted to the consent authority before the determination of that Development Application.

  • Development Report means a written account of Licensee’s progress under the Development Plan having at least the information specified on Appendix B to this Agreement, and shall be sent to the address specified on Appendix B.

  • Phase 3 Clinical Trial means a pivotal clinical trial in humans performed to gain evidence with statistical significance of the efficacy of a product in a target population, and to obtain expanded evidence of safety for such product that is needed to evaluate the overall benefit-risk relationship of such product, to form the basis for approval of an NDA and to provide an adequate basis for physician labeling, as described in 21 C.F.R. § 312.21(c) or the corresponding regulation in jurisdictions other than the United States.

  • Phase 4 Clinical Trial means a Clinical Trial of a Product conducted after Regulatory Approval of such Product has been obtained from an appropriate Regulatory Authority, which trial is (a) conducted voluntarily by a Party to enhance marketing or scientific knowledge of the Product, or (b) conducted due to a request or requirement of a Regulatory Authority.

  • Clinical Trials means a controlled study in humans of the safety or efficacy of a Product, and includes, without limitation, such clinical trials as are designed to support expanded labeling or to satisfy the requirements of an Agency in connection with any Product Approval and any other human study used in research and Development of a Product.